Tian Zhang, MD

Adjunct Associate Professor in the Department of Medicine
Campus mail DUMC 103861, Durham, NC 27710
Phone (919) 668-4667
Email address tian.zhang2@duke.edu

Education and Training

  • Fellowship in Hematology-Oncology, Medicine, Duke University School of Medicine, 2012 - 2015
  • Internal Medicine Residency, Medicine, Duke University School of Medicine, 2009 - 2012
  • M.H.S., Duke University School of Medicine, 2019
  • M.D., Harvard Medical School, 2009

Publications

Brown, Landon C., Kunal Desai, Wei Wei, Emily N. Kinsey, Chester Kao, Daniel J. George, Brian I. Rini, Moshe C. Ornstein, and Tian Zhang. “Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.” J Immunother Cancer 9, no. 9 (September 2021). https://doi.org/10.1136/jitc-2021-003281.

PMID
34518292
Full Text

Coelho Barata, P. M., S. Gulati, A. Elliott, A. Rao, E. F. Burgess, R. McKay, H. J. Hammers, et al. “688P Gene expression profiling (GEP) signatures associated with markers of sensitivity to immune and angiogenic therapy in clear-cell renal cell carcinoma (ccRCC) with sarcomatoid/rhabdoid features.” In Annals of Oncology, 32:S705–S705. Elsevier BV, 2021. https://doi.org/10.1016/j.annonc.2021.08.084.

Full Text

George, Daniel J., Susan Halabi, Elisabeth I. Heath, A Oliver Sartor, Guru P. Sonpavde, Devika Das, Rhonda L. Bitting, et al. “A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate-resistant prostate cancer.” Cancer 127, no. 16 (August 15, 2021): 2954–65. https://doi.org/10.1002/cncr.33589.

PMID
33951180
Full Text

Min, Yuanzeng, Kyle C. Roche, Shaomin Tian, Michael J. Eblan, Karen P. McKinnon, Joseph M. Caster, Shengjie Chai, et al. “Author Correction: Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy.” Nat Nanotechnol 16, no. 6 (June 2021): 743–44. https://doi.org/10.1038/s41565-021-00864-w.

PMID
33580223
Full Text

Grivas, P., A. R. Khaki, T. M. Wise-Draper, B. French, C. Hennessy, C. -. Y. Hsu, Y. Shyr, et al. “Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.” Ann Oncol 32, no. 6 (June 2021): 787–800. https://doi.org/10.1016/j.annonc.2021.02.024.

PMID
33746047
Full Text

Pal, Sumanta K., Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Wang, et al. “A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.” In Journal of Clinical Oncology, 39:4507–4507. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4507.

Full Text

Tucker, Matthew D., Landon Carter Brown, Chester Kao, Nathan Hirshman, Emily Noelle Kinsey, Yu-Wei Chen, Kristin Kathleen Ancell, et al. “Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).” In Journal of Clinical Oncology, 39:4563–4563. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.4563.

Full Text

Regan, Jessica A., Michelle Green, Chester Kao, Eric Powers, Jadee Neff, John H. Strickler, Matthew Stuart McKinney, Svati H. Shah, and Tian Zhang. “Clonal hematopoiesis association with cardiac function and mortality in patients with solid tumors.” In Journal of Clinical Oncology, Vol. 39, 2021.

Scholars@Duke

Stewart, Tyler F., Nikhil V. Kotha, Hannah Elizabeth Dzimitrowicz, Dimitrios Makrakis, Ali Raza Khaki, Nicholas I. Simon, Ariel Ann Nelson, et al. “Efficacy of anti-PD(L)1 therapy for patients (Pts) with advanced urothelial carcinoma (aUC) with primary resistance to platinum-based chemotherapy (PC).” In Journal of Clinical Oncology, 39:e16515–e16515. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.e16515.

Full Text

Autio, Karen A., Celestia S. Higano, Luke T. Nordquist, Leonard Joseph Appleman, Tian Zhang, Xinhua Zhu, Hani M. Babiker, et al. “First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).” In Journal of Clinical Oncology, 39:2612–2612. American Society of Clinical Oncology (ASCO), 2021. https://doi.org/10.1200/jco.2021.39.15_suppl.2612.

Full Text

Pages